CPH’s US listing is happening tonight - trading as OTC: COPHF
Creso Pharma (ASX:CPH) is a medical cannabis and psychedelics company, a space which we believe is going to be very big over the next 10 years.
CPH today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.
While CPH releases a lot of random announcements, we think CPH’s US listing milestone is important and will be watching CPH open in the US tonight.
Follow CPH’s OTC trading here.
We are hoping CPH’s share price might pop and get some instant US investors attention given that CPH likes to promote itself - we hope CPH can emulate the $ billion plus market caps of its US-listed peers Mindmed and Compass Pathways.
We suspect that CPH will want to open in the US with a bang and they have probably engaged in some serious promotion over there to get their story out to the huge US investor market that loves medicinal cannabis and psychedelics investments.
We certainly know that CPH is not shy of promoting itself - they ask us to write to you about EVERY single announcement they release, no matter how random - all the way from their hemp based feedstock to stop pig herds biting each others tails in eastern Europe to the launch of its range of CBD teas for immunity, sleep and well being.
Some companies like to announce lots of random stuff often which makes it hard for investors to find and pay attention to the announcements that really matter.
We think less is more, so we only comment when we think an announcement is materially important for our investment, mainly new revenue or significant progress of products - we don’t really value MoU’s or partnerships without a guaranteed revenue component.
You can see what we think matters below in our CPH company milestones.
We think today’s announcement of CPH listing in the US is material and will be watching it on open tonight. Here is the link to watch.
Another recent CPH announcement we felt was important but not registered by the market was it’s target acquisition Halucenex securing a 20.3g supply of synthetic psilocybin (which is highly difficult to do) for its Phase II Clinical Trials.
Other CPH milestones that WE think are material and important to watch out for
We try to focus on the key announcements that matter - Here are the other milestones we think are important/material for our investment in CPH and what we are watching out for over the next few months:
Our investment plan for CPH
ASX:CPH is a medium term investment we hold and write about that is not currently in our long term portfolio. We took a position at 3c in October 2020 as a short term hold which upgraded to a medium hold after the company delivered. On March 26 2021 we increased our position at 19c. We are considering adding CPH to our long term portfolio if it can deliver a few more KEY milestones. We have been investing in CPH for a few years and have had a mixed experience, but are looking forward to see what they can deliver. The below investment plan refers only to our recent investments from 3c and 19c since we introduce our portfolio model.
What are we waiting for next?
In the coming weeks we are expecting:
- Completion of the acquisition of the psychedelics company
- Hopefully some more revenue generating cannabis sales
- Ticking off other milestones
All our CPH commentary
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
